JP2003534767A - ヒトオーファンｇタンパク質共役型受容体 - Google Patents
ヒトオーファンｇタンパク質共役型受容体Info
- Publication number
- JP2003534767A JP2003534767A JP2000584067A JP2000584067A JP2003534767A JP 2003534767 A JP2003534767 A JP 2003534767A JP 2000584067 A JP2000584067 A JP 2000584067A JP 2000584067 A JP2000584067 A JP 2000584067A JP 2003534767 A JP2003534767 A JP 2003534767A
- Authority
- JP
- Japan
- Prior art keywords
- seq
- human
- protein
- cdna
- receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 title abstract description 73
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 title abstract description 73
- 102000005962 receptors Human genes 0.000 claims description 117
- 108020003175 receptors Proteins 0.000 claims description 117
- 239000002299 complementary DNA Substances 0.000 claims description 83
- 239000013612 plasmid Substances 0.000 claims description 45
- 101000887490 Homo sapiens Guanine nucleotide-binding protein G(z) subunit alpha Proteins 0.000 claims description 39
- 102000052301 human GNAZ Human genes 0.000 claims description 39
- 239000013598 vector Substances 0.000 claims description 37
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 102000027257 transmembrane receptors Human genes 0.000 abstract description 2
- 108091008578 transmembrane receptors Proteins 0.000 abstract description 2
- 239000013615 primer Substances 0.000 description 26
- 108091006027 G proteins Proteins 0.000 description 25
- 102000030782 GTP binding Human genes 0.000 description 25
- 108091000058 GTP-Binding Proteins 0.000 description 25
- 210000004027 cell Anatomy 0.000 description 23
- 239000006274 endogenous ligand Substances 0.000 description 22
- 230000014509 gene expression Effects 0.000 description 22
- 150000001875 compounds Chemical class 0.000 description 20
- 239000012634 fragment Substances 0.000 description 20
- 238000006243 chemical reaction Methods 0.000 description 19
- 108090000623 proteins and genes Proteins 0.000 description 17
- 210000001519 tissue Anatomy 0.000 description 15
- 108020004414 DNA Proteins 0.000 description 14
- 230000000692 anti-sense effect Effects 0.000 description 13
- 238000000034 method Methods 0.000 description 13
- 238000012216 screening Methods 0.000 description 13
- 239000003814 drug Substances 0.000 description 12
- 238000003757 reverse transcription PCR Methods 0.000 description 12
- 238000003556 assay Methods 0.000 description 11
- 108020004705 Codon Proteins 0.000 description 10
- 108091008880 orphan GPCRs Proteins 0.000 description 10
- 108091081024 Start codon Proteins 0.000 description 9
- 230000003321 amplification Effects 0.000 description 9
- 238000003199 nucleic acid amplification method Methods 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 238000013459 approach Methods 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- 102000037865 fusion proteins Human genes 0.000 description 8
- 108020001507 fusion proteins Proteins 0.000 description 8
- 230000003834 intracellular effect Effects 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 230000004913 activation Effects 0.000 description 7
- 210000004556 brain Anatomy 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 239000011543 agarose gel Substances 0.000 description 6
- 230000027455 binding Effects 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 210000004962 mammalian cell Anatomy 0.000 description 6
- 239000000556 agonist Substances 0.000 description 5
- 230000008878 coupling Effects 0.000 description 5
- 238000010168 coupling process Methods 0.000 description 5
- 238000005859 coupling reaction Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 210000002216 heart Anatomy 0.000 description 5
- 150000007523 nucleic acids Chemical group 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 230000019491 signal transduction Effects 0.000 description 5
- XOFLBQFBSOEHOG-UUOKFMHZSA-N γS-GTP Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=S)[C@@H](O)[C@H]1O XOFLBQFBSOEHOG-UUOKFMHZSA-N 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000004031 partial agonist Substances 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 108700026244 Open Reading Frames Proteins 0.000 description 3
- 238000010240 RT-PCR analysis Methods 0.000 description 3
- 238000012300 Sequence Analysis Methods 0.000 description 3
- 108010006785 Taq Polymerase Proteins 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000018 receptor agonist Substances 0.000 description 3
- 229940044601 receptor agonist Drugs 0.000 description 3
- 125000006850 spacer group Chemical group 0.000 description 3
- 210000001541 thymus gland Anatomy 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 108010005415 G2A receptor Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101001017968 Homo sapiens Leukotriene B4 receptor 1 Proteins 0.000 description 2
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 2
- 102100033374 Leukotriene B4 receptor 1 Human genes 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 102000016978 Orphan receptors Human genes 0.000 description 2
- 108070000031 Orphan receptors Proteins 0.000 description 2
- 108091027981 Response element Proteins 0.000 description 2
- 241000566107 Scolopax Species 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- 102000014384 Type C Phospholipases Human genes 0.000 description 2
- 108010079194 Type C Phospholipases Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 102000030621 adenylate cyclase Human genes 0.000 description 2
- 108060000200 adenylate cyclase Proteins 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 102000005936 beta-Galactosidase Human genes 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 230000008512 biological response Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000006552 constitutive activation Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 150000001982 diacylglycerols Chemical class 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 230000031146 intracellular signal transduction Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000007423 screening assay Methods 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102100033040 Carbonic anhydrase 12 Human genes 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- 102000005636 Cyclic AMP Response Element-Binding Protein Human genes 0.000 description 1
- 108010045171 Cyclic AMP Response Element-Binding Protein Proteins 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 101710096438 DNA-binding protein Proteins 0.000 description 1
- 206010011953 Decreased activity Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 102000013446 GTP Phosphohydrolases Human genes 0.000 description 1
- 108091006109 GTPases Proteins 0.000 description 1
- 108091006065 Gs proteins Proteins 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 101000867855 Homo sapiens Carbonic anhydrase 12 Proteins 0.000 description 1
- 101001024391 Homo sapiens Neuromedin-U receptor 1 Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 102100035314 Neuromedin-U receptor 1 Human genes 0.000 description 1
- 108091036407 Polyadenylation Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000124033 Salix Species 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- 108010006886 Vitrogen Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 238000010256 biochemical assay Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229940095074 cyclic amp Drugs 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- REQPQFUJGGOFQL-UHFFFAOYSA-N dimethylcarbamothioyl n,n-dimethylcarbamodithioate Chemical compound CN(C)C(=S)SC(=S)N(C)C REQPQFUJGGOFQL-UHFFFAOYSA-N 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 238000010441 gene drive Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 210000003093 intracellular space Anatomy 0.000 description 1
- VNYSSYRCGWBHLG-AMOLWHMGSA-N leukotriene B4 Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O VNYSSYRCGWBHLG-AMOLWHMGSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000001525 receptor binding assay Methods 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000002356 skeleton Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
- C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- External Artificial Organs (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (47)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10921398P | 1998-11-20 | 1998-11-20 | |
| US60/109,213 | 1998-11-20 | ||
| US12041699P | 1999-02-16 | 1999-02-16 | |
| US60/120,416 | 1999-02-16 | ||
| US12185299P | 1999-02-26 | 1999-02-26 | |
| US60/121,852 | 1999-02-26 | ||
| US12394999P | 1999-03-12 | 1999-03-12 | |
| US12394699P | 1999-03-12 | 1999-03-12 | |
| US60/123,949 | 1999-03-12 | ||
| US60/123,946 | 1999-03-12 | ||
| US13713199P | 1999-05-28 | 1999-05-28 | |
| US13643799P | 1999-05-28 | 1999-05-28 | |
| US13643699P | 1999-05-28 | 1999-05-28 | |
| US13643999P | 1999-05-28 | 1999-05-28 | |
| US13656799P | 1999-05-28 | 1999-05-28 | |
| US13712799P | 1999-05-28 | 1999-05-28 | |
| US60/136,567 | 1999-05-28 | ||
| US60/137,131 | 1999-05-28 | ||
| US60/136,436 | 1999-05-28 | ||
| US60/136,437 | 1999-05-28 | ||
| US60/136,439 | 1999-05-28 | ||
| US60/137,127 | 1999-05-28 | ||
| US14144899P | 1999-06-29 | 1999-06-29 | |
| US60/141,448 | 1999-06-29 | ||
| US15663499P | 1999-09-29 | 1999-09-29 | |
| US15665399P | 1999-09-29 | 1999-09-29 | |
| US15655599P | 1999-09-29 | 1999-09-29 | |
| US15663399P | 1999-09-29 | 1999-09-29 | |
| US60/156,555 | 1999-09-29 | ||
| US60/156,633 | 1999-09-29 | ||
| US60/156,653 | 1999-09-29 | ||
| US60/156,634 | 1999-09-29 | ||
| US15728299P | 1999-10-01 | 1999-10-01 | |
| US15729499P | 1999-10-01 | 1999-10-01 | |
| US15728199P | 1999-10-01 | 1999-10-01 | |
| US15728099P | 1999-10-01 | 1999-10-01 | |
| US15729399P | 1999-10-01 | 1999-10-01 | |
| US60/157,280 | 1999-10-01 | ||
| US60/157,281 | 1999-10-01 | ||
| US60/157,294 | 1999-10-01 | ||
| US60/157,293 | 1999-10-01 | ||
| US60/157,282 | 1999-10-01 | ||
| US41676099A | 1999-10-12 | 1999-10-12 | |
| US41704499A | 1999-10-12 | 1999-10-12 | |
| US09/416,760 | 1999-10-12 | ||
| US09/417,044 | 1999-10-12 | ||
| PCT/US1999/023687 WO2000031258A2 (en) | 1998-11-20 | 1999-10-13 | Human orphan g protein-coupled receptors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004132989A Division JP2004267216A (ja) | 1998-11-20 | 2004-04-28 | ヒトオーファンｇタンパク質共役型受容体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003534767A true JP2003534767A (ja) | 2003-11-25 |
| JP2003534767A5 JP2003534767A5 (enExample) | 2005-11-17 |
Family
ID=27586698
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000584067A Withdrawn JP2003534767A (ja) | 1998-11-20 | 1999-10-13 | ヒトオーファンｇタンパク質共役型受容体 |
| JP2004132989A Withdrawn JP2004267216A (ja) | 1998-11-20 | 2004-04-28 | ヒトオーファンｇタンパク質共役型受容体 |
| JP2007129923A Pending JP2007209352A (ja) | 1998-11-20 | 2007-05-15 | ヒトオーファンｇタンパク質共役型受容体 |
| JP2008033839A Pending JP2008133300A (ja) | 1998-11-20 | 2008-02-14 | ヒトオーファンｇタンパク質共役型受容体 |
| JP2009159339A Withdrawn JP2009298791A (ja) | 1998-11-20 | 2009-07-03 | ヒトオーファンｇタンパク質共役型受容体 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004132989A Withdrawn JP2004267216A (ja) | 1998-11-20 | 2004-04-28 | ヒトオーファンｇタンパク質共役型受容体 |
| JP2007129923A Pending JP2007209352A (ja) | 1998-11-20 | 2007-05-15 | ヒトオーファンｇタンパク質共役型受容体 |
| JP2008033839A Pending JP2008133300A (ja) | 1998-11-20 | 2008-02-14 | ヒトオーファンｇタンパク質共役型受容体 |
| JP2009159339A Withdrawn JP2009298791A (ja) | 1998-11-20 | 2009-07-03 | ヒトオーファンｇタンパク質共役型受容体 |
Country Status (12)
| Country | Link |
|---|---|
| EP (8) | EP2295574A1 (enExample) |
| JP (5) | JP2003534767A (enExample) |
| KR (5) | KR100963367B1 (enExample) |
| AT (3) | ATE366815T1 (enExample) |
| AU (2) | AU770056B2 (enExample) |
| CA (2) | CA2645717A1 (enExample) |
| DK (3) | DK1133559T3 (enExample) |
| ES (3) | ES2289610T3 (enExample) |
| IL (2) | IL142538A0 (enExample) |
| NZ (3) | NZ511087A (enExample) |
| PT (3) | PT1584683E (enExample) |
| WO (1) | WO2000031258A2 (enExample) |
Families Citing this family (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1690939B8 (en) | 1998-03-12 | 2010-10-13 | Astellas Pharma Inc. | Novel G protein-coupled receptor proteins |
| JP2002512780A (ja) * | 1998-04-24 | 2002-05-08 | スミスクライン ビーチャム コーポレーション | 新規７ｔｍ受容体ａｘｏｒ−２のクローニング |
| US6071722A (en) * | 1998-04-24 | 2000-06-06 | Smithkline Beecham Corporation | Nucleic acids encoding a G-protein coupled 7TM receptor (AXOR-1) |
| WO2000026339A2 (en) * | 1998-11-03 | 2000-05-11 | Smithkline Beecham Corporation | Axor14, a g-protein coupled receptor |
| US7816492B2 (en) | 1998-11-20 | 2010-10-19 | Arena Pharmaceuticals, Inc. | Human G protein-coupled receptors |
| USRE42190E1 (en) | 1998-11-20 | 2011-03-01 | Arena Pharmaceuticals, Inc. | Method of identifying a compound for inhibiting or stimulating human G protein-coupled receptors |
| US20030017528A1 (en) | 1998-11-20 | 2003-01-23 | Ruoping Chen | Human orphan G protein-coupled receptors |
| US6221660B1 (en) | 1999-02-22 | 2001-04-24 | Synaptic Pharmaceutical Corporation | DNA encoding SNORF25 receptor |
| WO2000050458A1 (en) * | 1999-02-26 | 2000-08-31 | Smithkline Beecham Corporation | Cloning of a p2y-like 7tm receptor (axor17) |
| US6620615B1 (en) * | 1999-04-23 | 2003-09-16 | Curagen Corporation | G-protein coupled receptor—encoding nucleic acids |
| EP1189944A4 (en) * | 1999-06-21 | 2002-09-11 | Smithkline Beecham Corp | AXOR16, R CEPTEUR COUPL UNE PROT INE G |
| JP2003504054A (ja) * | 1999-07-13 | 2003-02-04 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | Ｇ−タンパク質共役型受容体およびそのｄｎａ配列 |
| EP1198569A1 (en) * | 1999-07-30 | 2002-04-24 | MERCK PATENT GmbH | G-protein coupled receptor and dna sequences thereof |
| WO2001016179A1 (fr) * | 1999-08-27 | 2001-03-08 | Takeda Chemical Industries, Ltd. | Nouvelle proteine receptrice couplee a une proteine g, et son adn |
| US6998255B1 (en) | 1999-09-24 | 2006-02-14 | Solvay Pharmaceuticals B.V. | Human G-protein coupled receptor |
| GB9923177D0 (en) * | 1999-09-30 | 1999-12-01 | Pfizer Ltd | Novel polypeptide |
| US6204017B1 (en) | 1999-10-07 | 2001-03-20 | Schering Corporation | Polynucleotide encoding a histamine receptor |
| GB9923890D0 (en) * | 1999-10-08 | 1999-12-08 | Pfizer Ltd | Novel polypeptide |
| GB9923893D0 (en) * | 1999-10-08 | 1999-12-08 | Pfizer Ltd | Novel polypeptide |
| GB9924956D0 (en) * | 1999-10-21 | 1999-12-22 | Pfizer Ltd | Novel polypeptide |
| GB9924960D0 (en) * | 1999-10-21 | 1999-12-22 | Pfizer Ltd | Novel polypeptide |
| WO2001031014A2 (en) * | 1999-10-27 | 2001-05-03 | Pharmacia & Upjohn Company | G protein-coupled receptors expressed in human brain |
| ATE375390T1 (de) * | 1999-10-29 | 2007-10-15 | Pfizer | G-protein-gekoppelter rezeptor-ähnliche proteine |
| EP1226250A2 (en) * | 1999-11-03 | 2002-07-31 | MERCK PATENT GmbH | Gpcr-kd5 polypeptides and dna sequences thereof |
| US6461836B1 (en) | 1999-11-05 | 2002-10-08 | Smithkline Beecham Corporation | Molecular cloning of a 7TM receptor (AxOR34) and screening methods thereof |
| EP1237909A2 (en) * | 1999-11-16 | 2002-09-11 | PHARMACIA & UPJOHN COMPANY | Human g protein-coupled receptors |
| US7029857B1 (en) | 1999-12-17 | 2006-04-18 | H. Lundbeck A/S | Processes for obtaining compounds employing SNORF72 receptors |
| WO2001046414A1 (fr) * | 1999-12-20 | 2001-06-28 | Banyu Pharmaceutical Co., Ltd. | Nouvelle proteine receptrice couplee a la proteine de fixation de guanosine triphosphate, bg26 |
| AU2288601A (en) | 1999-12-23 | 2001-07-03 | Millennium Pharmaceuticals, Inc. | P2Y12 receptor |
| WO2001048189A1 (fr) * | 1999-12-28 | 2001-07-05 | Helix Research Institute | Nouveaux recepteurs couples a une proteine de liaison au guanosine triphosphate, genes de ces derniers, et production et utilisation de ces derniers |
| GB0001700D0 (en) * | 2000-01-25 | 2000-03-15 | Glaxo Group Ltd | Novel protein |
| DE60129933T2 (de) | 2000-02-04 | 2008-02-14 | Takeda Pharmaceutical Co. Ltd. | Verfahren zum screening |
| ATE356208T1 (de) * | 2000-03-14 | 2007-03-15 | Bayer Healthcare Ag | Regulation des menschliches lipoxin a4 rezeptor- ähnliches protein |
| EP1268777A2 (en) * | 2000-03-17 | 2003-01-02 | Bayer Aktiengesellschaft | Regulation of human leukotriene b 4?-like g protein-coupled receptor |
| EP1270589A4 (en) * | 2000-03-21 | 2004-09-29 | Yamanouchi Pharma Co Ltd | NEW LEUKOTRIENB4 RECEPTOR |
| WO2001073021A1 (fr) * | 2000-03-28 | 2001-10-04 | Takeda Chemical Industries, Ltd. | Nouvelle proteine receptrice couplee a une proteine g et adn associe |
| AU4467301A (en) * | 2000-03-31 | 2001-10-08 | Helix Research Institute | Novel guanosine triphosphate-binding protein-coupled receptor gprv53, gene thereof and production and use of the same |
| WO2001077326A1 (fr) * | 2000-04-12 | 2001-10-18 | Takeda Chemical Industries, Ltd. | Proteine receptrice couplee a la proteine g et son adn |
| EP1178110A1 (en) * | 2000-08-01 | 2002-02-06 | Aventis Pharma Deutschland GmbH | EDG8 receptor for sphingosine 1-phosphate , its preparation and use |
| EP1287133B1 (en) * | 2000-05-18 | 2006-12-13 | Bayer HealthCare AG | Regulation of human dopamine-like g protein-coupled receptor |
| WO2002000719A2 (en) * | 2000-06-23 | 2002-01-03 | Tularik Inc. | Human and mouse g-protein couipled receptors |
| JP2004501629A (ja) * | 2000-06-26 | 2004-01-22 | アクゾ・ノベル・エヌ・ベー | Ｇタンパク質共役受容体ｏｒｇ１０ |
| WO2002002599A2 (en) * | 2000-06-30 | 2002-01-10 | Ingenium Pharmaceuticals Ag | HUMAN G PROTEIN-COUPLED RECEPTOR IGPcR17, AND USES THEROF |
| WO2002004518A2 (en) * | 2000-07-06 | 2002-01-17 | Bayer Corporation | Human neuropeptide y-like g protein-coupled receptor |
| EP1311546A2 (en) * | 2000-08-09 | 2003-05-21 | Millenium Pharmaceuticals, Inc. | Methods for using 14266, a human g protein-coupled receptor |
| US6790608B2 (en) * | 2000-09-20 | 2004-09-14 | The Regents Of The University Of California | Methods of identifying and ADP-glucose receptor ligand, agonist or antagonist |
| AU2002210982A1 (en) | 2000-11-01 | 2002-05-15 | Yamanouchi Pharmaceutical Co..Ltd. | Method of screening antiplatelet |
| JP4178028B2 (ja) * | 2000-11-07 | 2008-11-12 | タケダ ケンブリッジ リミテッド | 受容体 |
| WO2002042461A2 (en) * | 2000-11-27 | 2002-05-30 | Arena Pharmaceuticals, Inc. | Endogenous and non-endogenous versions of human g protein-coupled receptors |
| US20030180813A1 (en) | 2000-12-01 | 2003-09-25 | Takahide Ohishi | Method of screening remedy for diabetes |
| WO2002052047A2 (en) * | 2000-12-22 | 2002-07-04 | Mergen Ltd. | Methods for identifying g-protein coupled receptors associated with diseases |
| US7220580B2 (en) | 2000-12-22 | 2007-05-22 | University Of South Florida | Sphingosine 1-phosphate receptor gene, sppr |
| GB0100782D0 (en) * | 2001-01-11 | 2001-02-21 | Glaxo Group Ltd | Assay |
| EP1382678B1 (en) * | 2001-04-25 | 2008-08-27 | Astellas Pharma Inc. | Guanosine triphosphate-binding protein-coupled recepotr place 6002312 and its gene and production and use of the same |
| US20030096299A1 (en) | 2001-07-09 | 2003-05-22 | Valerie Wittamer | Natural ligand of G protein coupled receptor ChemR23 and uses thereof |
| US7419658B2 (en) | 2001-07-09 | 2008-09-02 | Euroscreen S.A. | Isolated ligand of ChemerinR |
| US7858755B2 (en) | 2001-07-09 | 2010-12-28 | Euroscreen S.A. | Monoclonal antibodies that bind Chemerin polypeptide |
| US6946244B2 (en) * | 2001-08-07 | 2005-09-20 | Euroscreen, S.A. | Methods of identifying a ligand, an agonist, and an antagonist of G protein coupled receptor GPR86 (P2Y13) |
| MXPA04009959A (es) | 2002-04-12 | 2004-12-13 | Schering Corp | Ligandos del receptor acoplado a la proteina g y metodos. |
| AU2003261874A1 (en) * | 2002-09-02 | 2004-03-29 | Takeda Pharmaceutical Company Limited | Adrenocortical hormone secretion controller |
| JPWO2004033687A1 (ja) * | 2002-10-11 | 2006-02-09 | アステラス製薬株式会社 | 腎不全治療薬をスクリーニングする方法 |
| US7056685B1 (en) | 2002-11-05 | 2006-06-06 | Amgen Inc. | Receptor ligands and methods of modulating receptors |
| JP4516430B2 (ja) | 2002-12-20 | 2010-08-04 | メルク・シャープ・エンド・ドーム・コーポレイション | １−（アミノ）インダン並びに（１，２−ジヒドロ−３−アミノ）−ベンゾフラン、ベンゾチオフェン及びインドール |
| GEP20084540B (en) | 2003-01-14 | 2008-11-25 | Arena Pharm Inc | 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia |
| US7083933B1 (en) | 2003-05-09 | 2006-08-01 | Prosidion Limited | Methods for identification of modulators of OSGPR116 activity |
| EP1648488A4 (en) * | 2003-06-27 | 2007-01-24 | Tanox Inc | MEMBRANE PROTEIN EXPRESSED IN HUMAN MASTOCYTES |
| US7524638B1 (en) | 2003-06-27 | 2009-04-28 | Osi Pharmaceuticals, Inc. | Methods for identification of modulators of OSGPR114 or OSGPR78 activity, and their use in the treatment of disease |
| DOP2006000008A (es) | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1 |
| GB0508990D0 (en) * | 2005-05-03 | 2005-06-08 | Novartis Ag | Organic compounds |
| EP2410330A3 (en) | 2006-04-11 | 2012-06-13 | Arena Pharmaceuticals, Inc. | Methods of using GPR119 receptor to identify compounds useful for increasing bone mass in an individual |
| US7638541B2 (en) | 2006-12-28 | 2009-12-29 | Metabolex Inc. | 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine |
| JP5489997B2 (ja) | 2007-07-19 | 2014-05-14 | シマベイ セラピューティクス， インコーポレーテッド | 糖尿病および代謝疾患の治療のためのＲＵＰ３またはＧＰＲｌ１９受容体のアゴニストとしてのＮ−アザ環状置換ピロール、ピラゾール、イミダゾール、トリアゾールおよびテトラゾール誘導体 |
| EP2197873B1 (en) | 2007-09-20 | 2014-07-16 | Irm Llc | Compounds and compositions as modulators of gpr119 activity |
| EP2108960A1 (en) | 2008-04-07 | 2009-10-14 | Arena Pharmaceuticals, Inc. | Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY |
| AR077642A1 (es) | 2009-07-09 | 2011-09-14 | Arena Pharm Inc | Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo |
| ES2497566T3 (es) | 2009-10-01 | 2014-09-23 | Cymabay Therapeutics, Inc. | Sales de tetrazol-1-il-fenoximetil-tiazol-2-il-piperidinil-pirimidina sustituida |
| US8791100B2 (en) | 2010-02-02 | 2014-07-29 | Novartis Ag | Aryl benzylamine compounds |
| US20130023494A1 (en) | 2010-04-06 | 2013-01-24 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| CN109674753A (zh) | 2010-06-23 | 2019-04-26 | 希玛贝治疗股份有限公司 | 固态分散体 |
| JP5941916B2 (ja) | 2010-09-22 | 2016-06-29 | アリーナ ファーマシューティカルズ， インコーポレイテッド | Ｇｐｒ１１９レセプターのモジュレーターおよびそれに関連する障害の処置 |
| US20140018371A1 (en) | 2011-04-01 | 2014-01-16 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
| US20140066369A1 (en) | 2011-04-19 | 2014-03-06 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
| US20140051714A1 (en) | 2011-04-22 | 2014-02-20 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
| US20140038889A1 (en) | 2011-04-22 | 2014-02-06 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
| WO2012170702A1 (en) | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| WO2013055910A1 (en) | 2011-10-12 | 2013-04-18 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| WO2014074668A1 (en) | 2012-11-08 | 2014-05-15 | Arena Pharmaceuticals, Inc. | Modulators of gpr119 and the treatment of disorders related thereto |
| DK3242666T5 (da) | 2015-01-06 | 2025-01-20 | Arena Pharm Inc | Forbindelsee til anvendelse i behandling af tilstande, der er forbundet med SIP1-receptoren |
| JP6838744B2 (ja) | 2015-06-22 | 2021-03-03 | アリーナ ファーマシューティカルズ， インコーポレイテッド | Ｓ１Ｐ１レセプター関連障害における使用のための（Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸（化合物１）の結晶性Ｌ−アルギニン塩 |
| US10292983B2 (en) | 2016-08-03 | 2019-05-21 | Cymabay Therapeutics, Inc. | Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions |
| WO2018236896A1 (en) | 2017-06-19 | 2018-12-27 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of nafld and nash |
| ES2987794T3 (es) | 2018-06-06 | 2024-11-18 | Arena Pharm Inc | Procedimientos de tratamiento de afecciones relacionadas con el receptor S1P1 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0868510A2 (en) * | 1995-11-15 | 1998-10-07 | Cor Therapeutics, Inc. | P2u2 PURINERGIC RECEPTOR |
| EP0955808A1 (en) * | 1996-01-11 | 1999-11-17 | Human Genome Sciences, Inc. | Human g-protein coupled receptor |
| AU6017098A (en) * | 1997-01-21 | 1998-08-07 | Schering Corporation | Mammalian chemokines; receptors; reagents; uses |
| US6221627B1 (en) * | 1997-02-24 | 2001-04-24 | Smithkline Beecham Corporation | cDNA clone HDPB130 that encodes a novel human 7-transmembrane receptor |
| US5955303A (en) * | 1997-03-06 | 1999-09-21 | Incyte Pharmaceuticals, Inc. | Human chemokine receptor-like protein |
| US6555339B1 (en) * | 1997-04-14 | 2003-04-29 | Arena Pharmaceuticals, Inc. | Non-endogenous, constitutively activated human protein-coupled receptors |
| US6060272A (en) * | 1997-05-07 | 2000-05-09 | Human Genome Sciences, Inc. | Human G-protein coupled receptors |
| EP0899332A3 (en) * | 1997-08-15 | 2000-07-05 | Smithkline Beecham Corporation | The G-protein coupled receptor HFIAO41 |
| CA2239255A1 (en) * | 1997-10-23 | 1999-04-23 | Smithkline Beecham Corporation | Cdna clone hneaa81 that encodes a human 7-transmembrane receptor |
| US5932445A (en) * | 1997-11-07 | 1999-08-03 | Incyte Pharmaceuticals, Inc. | Signal peptide-containing proteins |
| US6252056B1 (en) * | 1997-11-11 | 2001-06-26 | Ono Pharmaceutical Co., Ltd. | Human lysophosphatidic acid receptor and use thereof |
| US6207412B1 (en) * | 1997-11-13 | 2001-03-27 | The Regents Of The University Of California | Identification of a G protein-coupled receptor transcriptionally regulated by protein tyrosine kinase signaling in hematopoietic cells |
| WO1999042484A1 (en) * | 1998-02-20 | 1999-08-26 | Smithkline Beecham Corporation | Fishboy, a g-protein coupled receptor |
| EP1690939B8 (en) * | 1998-03-12 | 2010-10-13 | Astellas Pharma Inc. | Novel G protein-coupled receptor proteins |
| AU3749499A (en) * | 1998-04-16 | 1999-11-01 | Millenium Pharmaceuticals, Inc. | Novel molecules of the bgckr-related protein family and uses thereof |
| SE9801455D0 (sv) * | 1998-04-24 | 1998-04-24 | Astra Pharma Inc | New receptor |
| JP2002512780A (ja) * | 1998-04-24 | 2002-05-08 | スミスクライン ビーチャム コーポレーション | 新規７ｔｍ受容体ａｘｏｒ−２のクローニング |
| US6071722A (en) * | 1998-04-24 | 2000-06-06 | Smithkline Beecham Corporation | Nucleic acids encoding a G-protein coupled 7TM receptor (AXOR-1) |
| CA2340334A1 (en) * | 1998-08-19 | 2000-03-02 | Millenium Pharmaceuticals, Inc. | 14274 receptor, a g-protein coupled receptor related to the edg receptor family |
| AU5578699A (en) * | 1998-08-20 | 2000-03-14 | Millennium Pharmaceuticals, Inc. | 14400 receptor, a g-protein coupled receptor |
| AU5784799A (en) * | 1998-08-24 | 2000-03-14 | Alphagene, Inc. | Secreted proteins and polynucleotides encoding them |
| AU5801099A (en) * | 1998-09-02 | 2000-03-21 | Millennium Pharmaceuticals, Inc. | 14926 receptor, a novel g-protein coupled receptor |
| IL142153A0 (en) * | 1998-10-13 | 2002-03-10 | Arena Pharm Inc | Non-endogenous, constitutively activated human g protein-coupled receptors |
| JP2004500013A (ja) * | 1998-10-16 | 2004-01-08 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | 新規ｇタンパク質共役受容体 |
| WO2000026369A1 (en) * | 1998-11-04 | 2000-05-11 | Chiron Corporation | Isolated vshk-1 receptor polypeptides and methods of use thereof |
| EP1127126B1 (en) * | 1998-11-06 | 2006-10-18 | Bayer HealthCare AG | G-protein coupled receptors, homologous to ebv-induced gpcr 2 (ebi-2). methods to seek for ligands thereof |
| US6221660B1 (en) * | 1999-02-22 | 2001-04-24 | Synaptic Pharmaceutical Corporation | DNA encoding SNORF25 receptor |
| US6689866B1 (en) * | 1999-03-09 | 2004-02-10 | Curagen Corporation | Polynucleotides and proteins encoded thereby |
| US6590938B1 (en) * | 1999-09-30 | 2003-07-08 | Conexant Systems, Inc. | DCT domain conversion of a higher definition signal to lower definition signal |
| GB9923177D0 (en) * | 1999-09-30 | 1999-12-01 | Pfizer Ltd | Novel polypeptide |
-
1999
- 1999-10-13 PT PT05003040T patent/PT1584683E/pt unknown
- 1999-10-13 AT AT05003040T patent/ATE366815T1/de active
- 1999-10-13 NZ NZ511087A patent/NZ511087A/en not_active IP Right Cessation
- 1999-10-13 EP EP10010658A patent/EP2295574A1/en not_active Withdrawn
- 1999-10-13 CA CA002645717A patent/CA2645717A1/en not_active Withdrawn
- 1999-10-13 KR KR1020087003578A patent/KR100963367B1/ko not_active Expired - Fee Related
- 1999-10-13 ES ES05003040T patent/ES2289610T3/es not_active Expired - Lifetime
- 1999-10-13 EP EP07001452A patent/EP1780280A1/en not_active Ceased
- 1999-10-13 EP EP05003040A patent/EP1584683B1/en not_active Expired - Lifetime
- 1999-10-13 JP JP2000584067A patent/JP2003534767A/ja not_active Withdrawn
- 1999-10-13 EP EP99972682A patent/EP1133559B1/en not_active Expired - Lifetime
- 1999-10-13 EP EP10008862A patent/EP2295572A1/en not_active Withdrawn
- 1999-10-13 WO PCT/US1999/023687 patent/WO2000031258A2/en not_active Ceased
- 1999-10-13 EP EP07008841A patent/EP1849866B1/en not_active Expired - Lifetime
- 1999-10-13 PT PT99972682T patent/PT1133559E/pt unknown
- 1999-10-13 DK DK99972682T patent/DK1133559T3/da active
- 1999-10-13 KR KR1020087024998A patent/KR20080104062A/ko not_active Withdrawn
- 1999-10-13 KR KR1020087003575A patent/KR100926209B1/ko not_active Expired - Fee Related
- 1999-10-13 IL IL14253899A patent/IL142538A0/xx unknown
- 1999-10-13 CA CA002348377A patent/CA2348377C/en not_active Expired - Fee Related
- 1999-10-13 ES ES07008841T patent/ES2308759T3/es not_active Expired - Lifetime
- 1999-10-13 PT PT07008841T patent/PT1849866E/pt unknown
- 1999-10-13 KR KR1020077018185A patent/KR100926208B1/ko not_active Expired - Fee Related
- 1999-10-13 NZ NZ537625A patent/NZ537625A/en not_active IP Right Cessation
- 1999-10-13 DK DK05003040T patent/DK1584683T3/da active
- 1999-10-13 AT AT07008841T patent/ATE396400T1/de active
- 1999-10-13 ES ES99972682T patent/ES2243095T3/es not_active Expired - Lifetime
- 1999-10-13 NZ NZ527622A patent/NZ527622A/en not_active IP Right Cessation
- 1999-10-13 AT AT99972682T patent/ATE301673T1/de active
- 1999-10-13 DK DK07008841T patent/DK1849866T3/da active
- 1999-10-13 KR KR1020017006279A patent/KR100765039B1/ko not_active Expired - Fee Related
- 1999-10-13 EP EP05005946A patent/EP1580271A3/en not_active Ceased
- 1999-10-13 AU AU37904/00A patent/AU770056B2/en not_active Ceased
- 1999-10-13 EP EP10010303A patent/EP2295573A1/en not_active Withdrawn
-
2001
- 2001-04-11 IL IL142538A patent/IL142538A/en not_active IP Right Cessation
-
2004
- 2004-04-28 JP JP2004132989A patent/JP2004267216A/ja not_active Withdrawn
- 2004-05-12 AU AU2004202147A patent/AU2004202147A1/en not_active Abandoned
-
2007
- 2007-05-15 JP JP2007129923A patent/JP2007209352A/ja active Pending
-
2008
- 2008-02-14 JP JP2008033839A patent/JP2008133300A/ja active Pending
-
2009
- 2009-07-03 JP JP2009159339A patent/JP2009298791A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003534767A (ja) | ヒトオーファンｇタンパク質共役型受容体 | |
| US8097452B2 (en) | Human orphan G protein-coupled receptors | |
| US8198049B2 (en) | Nucleic acids encoding RUP3 and methods of using same | |
| USRE42190E1 (en) | Method of identifying a compound for inhibiting or stimulating human G protein-coupled receptors | |
| AU2009202228B2 (en) | Human Orphan G protein-Coupled receptor hRUP3 | |
| JP2003525018A (ja) | 非内在性の構成的に活性化されるヒトｇタンパク質共役型受容体 | |
| US20070072248A1 (en) | Constitutively activated human G protein coupled receptors | |
| HK1077082A (en) | Human orphan g protein-coupled receptors | |
| HK1155771A (en) | Human orphan g protein-coupled receptors | |
| HK1098510A (en) | Human orphan g protein-coupled receptors | |
| HK1103763B (en) | Human orphan g protein-coupled receptor rup3 | |
| JP2003525018A6 (ja) | 非内在性の構成的に活性化されるヒトｇタンパク質共役型受容体 | |
| HK1077081A1 (en) | Human orphan g protein-coupled receptor rup3 | |
| HK1077081B (en) | Human orphan g protein-coupled receptor rup3 | |
| HK1037675B (en) | Human orphan g protein-coupled receptor rup3 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040428 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040428 |
|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20040506 |
|
| A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20040723 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20041119 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20050222 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20050408 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050808 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050912 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050928 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20050912 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20050928 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20051031 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20051118 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20061101 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20061101 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20070326 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070918 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070925 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20080104 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20080806 |